Celltrion Healthcare

Truxima

Truxima

Truxima® is the world's first oncology mAB biosimilar developed by Celltrion and approved by FDA and EMA.

• Product Name : Truxima®
• INN : Rituximab
• Indications : Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), Rheumatoid Arthritis(RA), Granulomatosis with Polyangiitis(GPA), Microscopic Polyangiitis(MPA)
• Protein Type : Monoclonal antibody (mAb)
• Mechanism of Action : It targets the CD20 antigen expressed on the surface of malignant B-cells and enabling the immune response that involves B-cell lysis.
• Drug Approval Status : Korea, USA, Europe, Canada, Brazil, etc.